Stem cell showdown: donor or self? new trial aims to improve lymphoma outcomes
NCT ID NCT07253129
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two types of stem cell transplants for people with peripheral T-cell lymphoma whose cancer only partially responded to first treatment. One group receives their own stem cells, the other receives cells from a matched donor. The goal is to see which approach leads to better two-year survival without cancer progression. The trial plans to enroll 88 participants across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stem cell transplant (either from a donor or the patient's own cells)
What this could lead to
If successful, this could show which type of stem cell transplant offers better long-term control for patients whose lymphoma only partially shrank after initial treatment.
What could go wrong
This is a relatively small, early-stage study (88 people) and results may not apply to all patients. Stem cell transplants carry serious risks like infection, graft-versus-host disease, and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••